[Immunogenicity and safety of prepandemic vaccines against H5N1 avian flu]

Llanos-Mendez A
Record ID 32011000509
Authors' recommendations: The results suggest the vaccine against H5N1 avian influenza based on fractionated inactivated virus formulated with a low amount of antigen (3.8μg) together with a oil in water emulsion (ASO3) as adjuvant, would represent the best option in the case of a pandemic.Nevertheless, the lack of standardization of the serological tests, as well as the limitations of the criteria used to evaluate the immunogenicity data, make the comparison of the results of the different tests difficult, making it necessary to interpret them with caution.The safety and tolerability profile of the studied vaccines can be considered clinically acceptable given the high risk of serious illness and death associated with H5N1 avian influenza.
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Humans
  • Influenza A Virus, H5N1 Subtype
  • Vaccination
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.